FY2025 EPS Estimates for HealthEquity, Inc. (NASDAQ:HQY) Boosted by Analyst

HealthEquity, Inc. (NASDAQ:HQY) – Equities research analysts at Zacks Research lifted their FY2025 earnings per share estimates for shares of HealthEquity in a report issued on Tuesday, September 24th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.25 per share for the year, up from their previous estimate of $2.15. The consensus estimate for HealthEquity’s current full-year earnings is $2.25 per share. Zacks Research also issued estimates for HealthEquity’s Q4 2025 earnings at $0.52 EPS, Q2 2026 earnings at $0.67 EPS, Q4 2026 earnings at $0.80 EPS, FY2026 earnings at $2.81 EPS, Q1 2027 earnings at $0.82 EPS, Q2 2027 earnings at $0.88 EPS and FY2027 earnings at $3.55 EPS.

HQY has been the topic of a number of other research reports. Robert W. Baird upped their price objective on HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 4th. Bank of America decreased their price objective on shares of HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Raymond James raised their price objective on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. Royal Bank of Canada reissued an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Finally, Barrington Research reissued an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $103.83.

HealthEquity Stock Up 1.6 %

NASDAQ:HQY opened at $79.93 on Friday. HealthEquity has a 52-week low of $61.81 and a 52-week high of $88.26. The stock has a 50-day simple moving average of $76.29 and a 200 day simple moving average of $79.26. The company has a market cap of $6.95 billion, a PE ratio of 86.88, a PEG ratio of 1.25 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10.

Institutional Trading of HealthEquity

Large investors have recently made changes to their positions in the company. Lindbrook Capital LLC increased its stake in HealthEquity by 22.7% during the 1st quarter. Lindbrook Capital LLC now owns 698 shares of the company’s stock valued at $57,000 after purchasing an additional 129 shares in the last quarter. Truist Financial Corp grew its holdings in shares of HealthEquity by 7.0% during the second quarter. Truist Financial Corp now owns 2,864 shares of the company’s stock valued at $247,000 after buying an additional 188 shares during the last quarter. O Shaughnessy Asset Management LLC increased its position in shares of HealthEquity by 3.9% during the first quarter. O Shaughnessy Asset Management LLC now owns 5,219 shares of the company’s stock worth $426,000 after acquiring an additional 197 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of HealthEquity by 7.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,854 shares of the company’s stock worth $246,000 after acquiring an additional 198 shares during the last quarter. Finally, Capstone Investment Advisors LLC raised its holdings in shares of HealthEquity by 7.0% in the 4th quarter. Capstone Investment Advisors LLC now owns 3,710 shares of the company’s stock worth $246,000 after acquiring an additional 243 shares during the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at HealthEquity

In other HealthEquity news, Director Frank Corvino sold 7,705 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $81.89, for a total value of $630,962.45. Following the sale, the director now owns 6,070 shares in the company, valued at approximately $497,072.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $81.89, for a total value of $630,962.45. Following the sale, the director now directly owns 6,070 shares of the company’s stock, valued at approximately $497,072.30. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.